Bloom Burton Weighs in on Zymeworks FY2025 Earnings

Key Points

• Zymeworks Inc. is projected to earn ($1.13) per share in FY2025, which is an improvement from the current consensus estimate of ($1.39) per share for the full year.
• The company reported a significant revenue increase of 153.2% year-over-year for the last quarter, bringing in $48.73 million, far surpassing analyst expectations.
• Zymeworks has a current average price target of $21.43, with most analysts rating the stock as a "Moderate Buy."

Zymeworks Inc. (NYSE:ZYME - Free Report) - Stock analysts at Bloom Burton issued their FY2025 earnings per share (EPS) estimates for Zymeworks in a research report issued on Wednesday, September 3rd. Bloom Burton analyst D. Martin anticipates that the company will post earnings per share of ($1.13) for the year. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. Bloom Burton also issued estimates for Zymeworks' FY2026 earnings at ($1.93) EPS and FY2027 earnings at ($2.11) EPS.

Zymeworks (NYSE:ZYME - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.55. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.The company had revenue of $48.73 million during the quarter, compared to the consensus estimate of $17.18 million. During the same quarter last year, the company earned ($0.49) earnings per share. Zymeworks's quarterly revenue was up 153.2% compared to the same quarter last year.

A number of other research firms also recently commented on ZYME. HC Wainwright reissued a "neutral" rating and issued a $13.00 target price on shares of Zymeworks in a report on Thursday, July 3rd. TD Cowen started coverage on Zymeworks in a report on Tuesday, May 20th. They issued a "buy" rating for the company. TD Securities started coverage on Zymeworks in a report on Tuesday, May 20th. They issued a "buy" rating for the company. Finally, Citigroup lifted their price target on Zymeworks from $19.00 to $22.00 and gave the stock a "buy" rating in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $21.43.

Zymeworks Stock Performance

Zymeworks stock traded up $0.97 during midday trading on Friday, reaching $15.05. The company's stock had a trading volume of 627,107 shares, compared to its average volume of 528,693. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $17.70. The stock's 50 day simple moving average is $13.63 and its 200 day simple moving average is $12.64. The firm has a market capitalization of $1.13 billion, a PE ratio of -10.03 and a beta of 1.27.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its stake in Zymeworks by 1,091.2% in the 1st quarter. CWM LLC now owns 2,299 shares of the company's stock valued at $27,000 after purchasing an additional 2,106 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company's stock valued at $62,000 after buying an additional 1,131 shares during the period. GAMMA Investing LLC grew its holdings in Zymeworks by 1,113.3% in the 1st quarter. GAMMA Investing LLC now owns 6,467 shares of the company's stock valued at $77,000 after buying an additional 5,934 shares during the period. BNP Paribas Financial Markets purchased a new stake in Zymeworks in the 4th quarter valued at about $108,000. Finally, Tower Research Capital LLC TRC grew its holdings in Zymeworks by 343.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company's stock valued at $142,000 after buying an additional 7,518 shares during the period. Institutional investors and hedge funds own 92.89% of the company's stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.